Vascular Biogenics (NASDAQ:VBLT) Releases Earnings Results, Hits Estimates

Share on StockTwits

Vascular Biogenics (NASDAQ:VBLT) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.13) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13), Morningstar.com reports. Vascular Biogenics had a negative net margin of 2,724.02% and a negative return on equity of 31.69%.

Shares of NASDAQ VBLT opened at $1.25 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.35 and a quick ratio of 8.35. Vascular Biogenics has a 52 week low of $0.60 and a 52 week high of $1.90. The company has a 50-day moving average of $1.30. The firm has a market capitalization of $45.21 million, a PE ratio of -2.02 and a beta of -0.33.

Several research firms have recently commented on VBLT. ValuEngine upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Chardan Capital restated a “hold” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research note on Tuesday. CIBC assumed coverage on shares of Vascular Biogenics in a research note on Thursday, June 27th. They issued an “outperform” rating for the company. Zacks Investment Research cut shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a research note on Thursday, May 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of Vascular Biogenics in a research note on Thursday, May 16th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Vascular Biogenics has a consensus rating of “Buy” and an average price target of $2.38.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. First Republic Investment Management Inc. raised its position in Vascular Biogenics by 7.4% during the first quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 10,000 shares during the last quarter. Athena Capital Advisors LLC raised its position in Vascular Biogenics by 216.7% during the second quarter. Athena Capital Advisors LLC now owns 35,000 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 23,950 shares during the last quarter. Finally, Menta Capital LLC acquired a new position in Vascular Biogenics during the first quarter worth about $35,000. Institutional investors own 6.80% of the company’s stock.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Article: Stock Symbols and CUSIP Explained

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Sigma Planning Corp Invests $214,000 in SPDR Portfolio S&P 500 Growth ETF
Sigma Planning Corp Invests $214,000 in SPDR Portfolio S&P 500 Growth ETF
IPG Photonics Co.  Shares Sold by Swiss National Bank
IPG Photonics Co. Shares Sold by Swiss National Bank
Brokerages Set Avid Technology, Inc.  Target Price at $9.17
Brokerages Set Avid Technology, Inc. Target Price at $9.17
Intercontinental Wealth Advisors LLC Has $524,000 Stock Holdings in Exxon Mobil Co.
Intercontinental Wealth Advisors LLC Has $524,000 Stock Holdings in Exxon Mobil Co.
Brokerages Set BRT Apartments Corp  Price Target at $13.50
Brokerages Set BRT Apartments Corp Price Target at $13.50
Amazon.com, Inc.  is Truehand Inc’s Largest Position
Amazon.com, Inc. is Truehand Inc’s Largest Position


© 2006-2019 Ticker Report